Nyrada FDA feedback: positive written response on Xolatryp pre-IND request
Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, has received written responses from the US Food and Drug Administration (FDA) to its Xolatryp® pre-IND meeting request. The FDA’s feedback was supportive of the proposed development pathway, with no major issues identified.
Xolatryp is the company’s lead candidate for reducing reperfusion injury in patients suffering a heart attack. Nyrada sought the feedback to support opening an Investigational New Drug application (IND) so that its PROTECT-MI Phase IIa trial can be conducted in the United States.
Nyrada remains on track to submit its US IND in the first half of the 2027 calendar year. The announcement was dated 13 October 2026.
Key highlights from the announcement:
- Nyrada received written FDA feedback in response to its pre-IND meeting request on the Xolatryp cardioprotection program.
- The response followed a review of Chemistry, Manufacturing and Controls (CMC) information, nonclinical efficacy, safety and toxicology data, and the clinical development briefing package.
- The feedback was supportive of the proposed development pathway with no major issues identified.
- The company remains on track to submit its US IND in the first half of the 2027 calendar year.
When big ASX news breaks, our subscribers know first
What the FDA reviewed and said
Scope of the FDA review
The FDA granted the Type B pre-IND meeting request and provided written responses. Its review covered Xolatryp’s CMC information, nonclinical efficacy, safety and toxicology data, and the clinical development briefing package.
According to the announcement, this was Nyrada’s first interaction with the FDA regarding the Xolatryp program.
Feedback by area
The announcement set out the FDA’s feedback across five areas, summarised below.
| Area | FDA position | Follow-up requested |
|---|---|---|
| Nonclinical | Completed nonclinical safety program appears sufficient in scope to support the Phase IIa study | Some additional information in the final IND submission |
| Clinical | Agreed in principle with the patient population; planned safety monitoring considered appropriate; overall clinical endpoint framework reasonable for a Phase IIa study | None stated |
| Cardiac Safety | Proceeding with Phase IIa before completing a thorough QT/QTc study is acceptable, based on Phase I cardiac safety data and proposed ECG and telemetry monitoring | None stated |
| CMC | Scope of testing for the drug substance and drug product appears appropriate to support IND submission; proposed specifications will be assessed during IND review | Additional stability information in the submission |
| Regulatory | A future Fast Track Designation request may be reasonable if the Phase III trial evaluates clinical endpoints reflecting serious aspects of STEMI | None stated |
The FDA also provided guidance on the potential use of existing nonclinical data to support subsequent clinical development, which may reduce the need for additional toxicology studies.
On Fast Track, the FDA’s wording was that a request may be reasonable under certain conditions. The announcement does not describe a designation as having been granted.
Understanding pre-IND meetings and Fast Track
A Type B pre-IND meeting is an early exchange with the FDA held before a company files an IND. It allows a sponsor to test its development plans against regulator views before submission.
Xolatryp targets reperfusion injury, which is damage that can occur when blood flow is restored after a heart attack. The PROTECT-MI trial is assessing patients with ST-Elevation Myocardial Infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), a procedure that reopens a blocked heart artery.
Fast Track Designation, according to the announcement, can provide more frequent interaction with the FDA and eligibility for rolling review of a marketing application.
Early alignment with the regulator matters for several reasons:
- It identifies data gaps, such as the additional nonclinical and stability information requested, before the IND is filed.
- It clarifies which studies may be needed, including guidance that may reduce additional toxicology studies.
- It confirms whether a Phase IIa study can proceed without a thorough QT/QTc study, which the FDA indicated is acceptable here.
For investors, these points bear on potential cost and timeline risk in the program.
Investment significance and next steps
Why it matters for the Xolatryp thesis
The feedback addresses the regulatory pathway for Xolatryp, Nyrada’s lead candidate. The FDA’s response was supportive of the proposed development pathway with no major issues identified.
Xolatryp has completed a Phase I clinical trial assessing safety, tolerability and pharmacokinetics, and the Phase IIa PROTECT-MI trial has commenced. According to the company, the candidate has shown efficacy in preclinical cardioprotection, neuroprotection and oncology models.
Announcement summary
The FDA’s feedback was “supportive of Nyrada’s proposed development pathway with no major issues identified.”
What happens next
Nyrada outlined the following next steps:
- Address the FDA’s recommendations as it prepares its IND submission.
- Continue preparing the IND package in parallel with trial activity.
- Submit the IND, which remains targeted for the first half of the 2027 calendar year.
The company’s current priority remains recruitment into PROTECT-MI. The announcement does not address funding or cash runway.
Get Biotech News Before the Market Moves
Big News Blast delivers FREE breaking ASX biotech and healthcare alerts to your inbox within minutes of release, complete with in-depth analysis and the full announcement. Join 20,000+ subscribers and stay ahead of the market. Click the “Free Alerts” button at Big News Blast to receive news the moment it breaks.